Vascular Physiology Unit, UCL Institute of Cardiovascular Science, 1 St. Martin's Le Grand, London, EC1A 4NP, UK.
Division of Imaging Sciences and Biomedical Engineering, King's College London, London, UK.
Cardiovasc Drugs Ther. 2019 Apr;33(2):207-219. doi: 10.1007/s10557-018-06846-w.
High-density lipoprotein cholesterol (HDL-c) has long been referred to as 'good cholesterol' due to its apparent inverse relationship with future CVD risk. More recent research has questioned a causal role for HDL-c in this relationship, however, as both genetic studies and numerous large-scale randomised controlled trials have found no evidence of a cardiovascular protective effect when HDL-c levels are raised. Instead, focus has switched to the functional properties of the HDL particle. Evidence suggests that both the composition and function of HDL may be significantly altered in the context of an inflammatory milieu, transforming the particle from a vasoprotective anti-atherogenic particle to a noxious pro-atherogenic equivalent. This review will summarise evidence relating HDL to CVD risk, explore recent evidence characterising changes in the composition and function of HDL that may occur in chronic inflammatory diseases, and discuss the potential for future HDL-modifying therapeutic interventions.
高密度脂蛋白胆固醇(HDL-c)长期以来一直被称为“好胆固醇”,因为它与未来 CVD 风险呈明显的反比关系。然而,最近的研究对 HDL-c 在这种关系中是否具有因果作用提出了质疑,因为遗传研究和许多大规模随机对照试验都没有发现当 HDL-c 水平升高时对心血管有保护作用的证据。相反,人们的注意力转向了 HDL 颗粒的功能特性。有证据表明,在炎症环境下,HDL 的组成和功能可能会发生显著改变,将颗粒从具有血管保护作用的抗动脉粥样硬化颗粒转变为有害的促动脉粥样硬化等效物。这篇综述将总结与 HDL 相关的 CVD 风险的证据,探讨最近关于慢性炎症性疾病中可能发生的 HDL 组成和功能变化的证据,并讨论未来 HDL 修饰治疗干预的可能性。